• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ATAD2过表达与结直肠癌的进展及预后相关。

ATAD2 overexpression is associated with progression and prognosis in colorectal cancer.

作者信息

Hou Mingming, Huang Rui, Song Yanni, Feng Di, Jiang Yang, Liu Ming

机构信息

Department of Orthopedics, The Fourth Affiliated Hospital of Harbin Medical University, Harbin.

Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin.

出版信息

Jpn J Clin Oncol. 2016 Mar;46(3):222-7. doi: 10.1093/jjco/hyv195. Epub 2016 Jan 26.

DOI:10.1093/jjco/hyv195
PMID:26819280
Abstract

OBJECTIVES

ATPase family AAA domain-containing 2 plays an important role in tumor progression including cell cycle, proliferation, apoptosis and chemoresistance. However, the expression of ATPase family AAA domain-containing 2 in colorectal cancer and its significance are still unclear. The aim of this study was to examine the expression of ATPase family AAA domain-containing 2 in colorectal cancer.

METHODS

Immunohistochemistry was used to determine the expression of ATPase family AAA domain-containing 2 in 155 colorectal cancer and 30 matched adjacent noncancerous tissues. The correlation of ATPase family AAA domain-containing 2 expression with clinicopathological variables was assessed using chi-square test. Patient survival was analyzed using the Kaplan-Meier and log-rank tests. Cox regression was performed for the multivariate analysis of prognostic factors.

RESULTS

High expression of ATPase family AAA domain-containing 2 was detected in 58.1% of the colorectal cancers and was significantly associated with advanced tumor-node-metastasis stage (P = 0.044), poor differentiation (P = 0.028), deep infiltration (P < 0.001), lymphovascular invasion (P = 0.006), lymph node metastasis (P = 0.024) and recurrence (P = 0.022). Patients with high ATPase family AAA domain-containing 2 expression had significantly poorer overall survival and disease-free survival (both P < 0.001) when compared with patients with low expression of ATPase family AAA domain-containing 2. The multivariate analysis showed that ATPase family AAA domain-containing 2 was an independent factor for both overall survival (P = 0.003; hazard ratio (HR): 2.356; 95% confidence interval (CI): 1.335-4.158) and disease-free survival (P = 0.001; HR: 2.643; 95% CI: 1.489-4.693).

CONCLUSIONS

These results showed that ATPase family AAA domain-containing 2 overexpression was associated with progression and prognosis of colorectal cancer.

摘要

目的

含AAA结构域的ATP酶家族成员2(ATPase family AAA domain-containing 2)在肿瘤进展过程中发挥重要作用,包括细胞周期、增殖、凋亡及化疗耐药性等方面。然而,含AAA结构域的ATP酶家族成员2在结直肠癌中的表达情况及其意义仍不明确。本研究旨在检测含AAA结构域的ATP酶家族成员2在结直肠癌中的表达。

方法

采用免疫组织化学法检测155例结直肠癌组织及30例配对的癌旁非癌组织中含AAA结构域的ATP酶家族成员2的表达。采用卡方检验评估含AAA结构域的ATP酶家族成员2表达与临床病理变量的相关性。使用Kaplan-Meier法和对数秩检验分析患者生存率。进行Cox回归分析以评估预后因素的多变量分析。

结果

58.1%的结直肠癌组织中检测到含AAA结构域的ATP酶家族成员2高表达,且与肿瘤-淋巴结-转移(TNM)分期较晚(P = 0.044)、低分化(P = 0.028)、浸润较深(P < 0.001)、淋巴管侵犯(P = 0.006)、淋巴结转移(P = 0.024)及复发(P = 0.022)显著相关。与含AAA结构域的ATP酶家族成员2低表达的患者相比,高表达患者的总生存期和无病生存期均显著较差(均P < 0.001)。多变量分析显示,含AAA结构域的ATP酶家族成员2是总生存期(P = 0.003;风险比(HR):2.356;95%置信区间(CI):1.335 - 4.158)和无病生存期(P = 0.001;HR:2.643;95% CI:1.489 - 4.693)的独立影响因素。

结论

这些结果表明,含AAA结构域的ATP酶家族成员2过表达与结直肠癌的进展及预后相关。

相似文献

1
ATAD2 overexpression is associated with progression and prognosis in colorectal cancer.ATAD2过表达与结直肠癌的进展及预后相关。
Jpn J Clin Oncol. 2016 Mar;46(3):222-7. doi: 10.1093/jjco/hyv195. Epub 2016 Jan 26.
2
ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker.ATAD2在胃癌中过表达,是一种独立的不良预后生物标志物。
Clin Transl Oncol. 2016 Aug;18(8):776-81. doi: 10.1007/s12094-015-1430-8. Epub 2015 Nov 2.
3
Silencing of ATPase family AAA domain-containing protein 2 inhibits migration and invasion of colorectal cancer cells.ATP 酶家族 AAA 结构域包含蛋白 2 的沉默抑制结直肠癌细胞的迁移和侵袭。
Neoplasma. 2016;63(6):846-855. doi: 10.4149/neo_2016_603.
4
CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer.细胞色素P450 24A1(CYP24A1)是人类结直肠癌进展和预后的潜在生物标志物。
Hum Pathol. 2016 Apr;50:101-8. doi: 10.1016/j.humpath.2015.11.008. Epub 2015 Nov 28.
5
Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis.ANCCA/ATAD2在子宫内膜癌中的过表达及其与肿瘤进展和不良预后的相关性。
Tumour Biol. 2015 Jun;36(6):4479-85. doi: 10.1007/s13277-015-3089-8. Epub 2015 May 2.
6
Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.神经胶质抗原2在肝细胞癌中的过表达预示预后不良。
World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649.
7
Prognostic value of ATPase family, AAA+ domain containing 2 expression in human cancers: A systematic review and meta-analysis.含AAA+结构域的ATP酶家族2在人类癌症中的表达的预后价值:一项系统综述和荟萃分析。
Medicine (Baltimore). 2019 Sep;98(39):e17180. doi: 10.1097/MD.0000000000017180.
8
Silence of ATAD2 inhibits proliferation of colorectal carcinoma via the Rb-E2F1 signaling.ATAD2 沉默通过 Rb-E2F1 信号抑制结直肠癌细胞的增殖。
Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):6055-6063. doi: 10.26355/eurrev_202006_21500.
9
Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.真核生物起始因子5A2(EIF5A2)的过表达与早期宫颈癌患者的癌症进展及不良预后相关。
Histopathology. 2016 Aug;69(2):276-87. doi: 10.1111/his.12933. Epub 2016 Mar 17.
10
DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.DEK 过表达作为结直肠癌不良预后的独立生物标志物。
BMC Cancer. 2013 Jul 31;13:366. doi: 10.1186/1471-2407-13-366.

引用本文的文献

1
ATAD2 promotes glycolysis and tumor progression in clear cell renal cell carcinoma by regulating the transcriptional activity of c-Myc.ATAD2通过调节c-Myc的转录活性促进透明细胞肾细胞癌的糖酵解和肿瘤进展。
Discov Oncol. 2023 May 26;14(1):79. doi: 10.1007/s12672-023-00696-1.
2
Upregulation Promotes Tumor Growth and Angiogenesis in Endometrial Cancer and Is Associated with Its Immune Infiltration.上调促进子宫内膜癌的肿瘤生长和血管生成,并与免疫浸润相关。
Dis Markers. 2022 Nov 28;2022:2334338. doi: 10.1155/2022/2334338. eCollection 2022.
3
Tumor-Promoting ATAD2 and Its Preclinical Challenges.
促瘤 ATAD2 及其临床前挑战。
Biomolecules. 2022 Jul 28;12(8):1040. doi: 10.3390/biom12081040.
4
Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain.结构洞察单乙酰化和二乙酰化组蛋白与 ATAD2B 溴结构域的识别。
J Med Chem. 2020 Nov 12;63(21):12799-12813. doi: 10.1021/acs.jmedchem.0c01178. Epub 2020 Oct 21.
5
Hitting a Moving Target: Simulation and Crystallography Study of ATAD2 Bromodomain Blockers.击中移动靶标:ATAD2 溴结构域阻滞剂的模拟与晶体学研究
ACS Med Chem Lett. 2020 Jun 30;11(8):1573-1580. doi: 10.1021/acsmedchemlett.0c00080. eCollection 2020 Aug 13.
6
Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma.ATAD2 过表达预示着口腔鳞状细胞癌预后不良。
Int J Med Sci. 2020 Jun 27;17(11):1598-1609. doi: 10.7150/ijms.46809. eCollection 2020.
7
Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis.长链非编码RNA CRNDE通过调控miR-126-5p/ATAD2轴促进结肠癌细胞进展和对紫杉醇的耐药性。
Onco Targets Ther. 2020 Jun 2;13:4931-4942. doi: 10.2147/OTT.S237580. eCollection 2020.
8
Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.肝细胞癌中 ATAD2 的临床价值与生物学功能的综合生物信息学分析。
Biomed Res Int. 2020 May 5;2020:8657468. doi: 10.1155/2020/8657468. eCollection 2020.
9
Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening.基于结构的虚拟筛选发现新型 ATAD2 溴结构域抑制剂,可在乳腺细胞中诱导细胞凋亡和自噬。
J Enzyme Inhib Med Chem. 2020 Dec;35(1):713-725. doi: 10.1080/14756366.2020.1740924.
10
ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.ATAD2 可预测卵巢癌患者的不良预后,是增殖的标志物。
Int J Oncol. 2020 Jan;56(1):219-231. doi: 10.3892/ijo.2019.4913. Epub 2019 Nov 14.